Startups
ProNAi Therapeutics, based in Kalamazoo and Ann Arbor, Michigan, is a clinical stage biotech company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer. Its lead drug PNT2258 is in the clinic in a Phase I study.
Co-Investors: Grand Angels, MI Angels, State of Michigan, BRCC, Sigvion Ventures
Co-Investors: Grand Angels, MI Angels, State of Michigan, BRCC, Sigvion Ventures
Overview
Location
Canada, British Columbia, Vancouver
Total raised
$72M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 13, 2014 | Series C round | $12M |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 22, 2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| Apr 22, 2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| Apr 21, 2014 | ProNAi raises $60 million to advance treatment to combat lymphoma | Among the applications for its PNT2258 treatment are diffuse large B-cell lymphoma, Richter’s transformation, and follicular lymphoma. The funds will also support drug manufacturing, advance development of preclinical drug candidates and th... |
| Apr 21, 2014 | ProNAi Therapeutics Closes $59.5M Series D Financing | ProNAi Therapeutics, Inc., a Plymouth, Michigan-based developer of novel nucleic acid therapeutics, closed a $59.5m Series D financing. The round was led by Vivo Capital, with participation from new investors Frazier Healthcare Ventures, Or... |
| Jan 13, 2014 | ProNAi Therapeutics Raises $12M in Series C Financing | ProNAi Therapeutics, Inc., a Plymouth, MI-based developer of nucleic acid therapeutics, closed a $12m Series C financing round. The round was led by Capital Midwest Fund and includes existing and new investors. Founded in 2004 and led by Mi... |
| Apr 11, 2012 | Using DNA to silence cancer-causing genes nets ProNAi $310K | In September 2010, the company advanced PNT2258 to a phase 1 trial for safety and tolerable dosage in patients with tumors for which there are no effective treatments. Results are expected later this year followed by the initiation of the n... |
| Dec 31, 2010 | Cancer therapeutics company ProNAi could raise $12 million | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recov... |
| Aug 28, 2007 | Life sciences briefing: Tuesday, Aug. 28, 2007 | Featured companies: ProNAi, Rubicor ProNAi raises $2M for IV cancer drugs — ProNAi, a Kalamazoo, Mich., biotech focused on intravenous cancer drugs, raised $2 million toward a $4 million bridge round, VentureWire reports (subscription requi... |
| ProNAi raises $60 million to advance treatment to combat lymphoma | Cancer drug developer ProNAi Therapeutics, which developed a nucleic acid-based DNA-interference technology to cause cancer cell death, has added nine new investors in an oversubscribed Series D round. The latest fundraise will help support... |
Show more
Reviews 0
FAQ about ProNAi Therapeutics
How much funding has ProNAi Therapeutics raised?
ProNAi Therapeutics has raised $72M in total across 2 funding rounds.
What funding rounds has ProNAi Therapeutics raised?
Parsers VC lists 2 funding rounds of ProNAi Therapeutics, among them a Series C round of $12M on Jan 13, 2014.
What has the press written about ProNAi Therapeutics?
Parsers VC has collected 12 articles mentioning ProNAi Therapeutics, among them “MoneyTree Reports $121M in MI Venture Deals Last Quarter” (Jul 22, 2014) and “ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug” (Apr 22, 2014).
Is ProNAi Therapeutics still active?
ProNAi Therapeutics is probably closed: its latest activity on Parsers VC dates from Jun 29, 2016.